1. Introduction
===============

Hepatocellular carcinoma (HCC) is the second most frequently diagnosed gastrointestinal tumor worldwide and one of the most lethal cancers, especially in less developed countries.^\[[@R1],[@R2]\]^ Most HCCs originate from chronic hepatic diseases, especially chronic hepatitis viral infections, such as hepatitis C virus in North America and hepatitis B virus in Asia.^\[[@R3]\]^ Hereditary liver disease and non-alcoholic fatty liver disease are also associated with HCC.^\[[@R4]\]^ HCC development is a long-lasting process involving genetic changes that accumulate over time.^\[[@R5]\]^ Although comprehensive treatments for HCC patients are available, their long-term survival remains dismal, owing to repeated recurrence and other therapies.^\[[@R6]\]^ Additionally, most patients with better survival rely on early diagnosis by serological tests and imaging. Histidine triad nucleotide-binding 2 (*HINT2*), a member of the HINT superfamily, exists extensively in several mammalian organs, including the liver, pancreas, and adrenal gland.^\[[@R7]\]^ It is reported that the *HINT2* protein is localized exclusively in the mitochondrial matrix of liver cells.^\[[@R8]\]^*HINT2* knock-out experiments confirmed that *HINT2* is related to lipid and glucose homeostasis in mitochondria and cells.^\[[@R9]\]^ Furthermore, *HINT2* is significantly down-regulated in colon carcinoma tissues,^\[[@R10]\]^ and down-regulation of *HINT2* induces colon carcinoma cell migration and invasion by promoting hypoxia inducible factor-2α.^\[[@R11]\]^ High expression of *HINT2* induced by progesterone or calcitriol plays a critical role in the inhibition of endometrial cancer cell growth by pathways that involve cell cycle arrest and apoptosis.^\[[@R12]\]^ In brief, *HINT2* may function as a tumor suppressor in certain types of carcinoma. Although a significant effect by *HINT2* on cancer pathobiology is evident, its clinical significance in HCC remains poorly elucidated.

In this study, we investigated *HINT2* mRNA expression in tumor tissues and adjacent non-tumor tissues from HCC patients and analyzed the correlations between *HINT2* expression and clinical and pathological parameters.

2. Materials and Methods
========================

2.1. Clinical samples and follow-up
-----------------------------------

A total of 106 paired tissues from different patients who underwent curative hepatectomy at the First Affiliated Hospital of Zhejiang University were selected. All consent forms were signed by the patients, and this research was authorized by the Ethics Committee of the First Affiliated Hospital of Zhejiang University. All patients met the pathological diagnostic criteria for HCC, and no patient received chemotherapy or radiation therapy before surgery. Each patient was followed up for 5 years or until death.

2.2. Total RNA extraction and cDNA synthesis
--------------------------------------------

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocol. The RNA concentration and purity were assessed at 260 and 280 nm. cDNA was synthesized from total RNA (2 μg) using M-MLV Reverse Transcriptase (Promega, San Luis Obispo, CA, USA) following the manufacturer\'s instructions.

2.3. Quantitative real-time PCR
-------------------------------

Quantitative real-time PCR was performed on the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using the SYBR Premix Dimer Eraser Kit (Takara Biotechnology, Dalian, Liaoning, China). Amplification reactions containing 1 μl cDNA template, 0.3 μl of the forward and reverse primer each (10 μM), 0.2 μl 50 × ROX Reference Dye II (Takara) and 5 μl 2 × SYBR Premix Dimer Eraser were mixed and brought to a total volume of 10 μl. The primer sequences were as follows: 5′-GGACACCTACTCCTTGTGGC-3′ (forward) and 5′-CCCATCGTTGATCACAAGTCG-3′ (reverse) for *HINT2* and 5′-CTTAGTTGCGTTACACCCTTTC-3′ (forward) and 5′-CACCTTCACCGTTCCAGTTT-3′ (reverse) for β-actin. Amplification reactions proceeded as follows: initial denaturation at 95 °C for 30 s, followed by 40 cycles at 95°C for 5 s, 55°C for 30 s and 72°C for 34 s. Relative quantification was performed using the comparative threshold cycle (2^−ΔΔCT^) method, with β-actin as the internal control. To evaluate data reproducibility, all real-time PCRs were performed in triplicate.

2.4. The Cancer Genome Atlas (TCGA) data analysis
-------------------------------------------------

The results of prognosis analysis of HINT2 mRNAs expression datasets were validated in the TCGA datasets. TCGA-hepatic cancer mRNA data and clinical data (level 3) of the corresponding patients (365 tumor tissue) were downloaded from the TCGA Data portal. We used median value of mRNA expression level as the cutoff value to divide the data into low and high group. The expression analyses were carried out using BRB-ArrayTools (version 4.5, National Cancer Institute, Bethesda, MD, USA). As a result, a dataset of 471 HCC patients was generated for further statistical analysis.

2.5. Statistical analysis
-------------------------

Continuous variables are presented as means ± standard deviation. The paired *t* test was used to analyze differences in *HINT2* mRNA expression between paired tissues. Pearson Chi-Squared test was used to compare categorical variables, and Student *t* test was used for continuous variables. As the median is not affected by extreme values (outliers), we chose to divide the patients into high and low *HINT2* expression groups according to the median *HINT2* expression value. The Kaplan--Meier method was performed for survival curves, and the log-rank test was used to compare differences. Multivariate analysis was performed using the Cox proportional hazard regression model. A two-tailed *P* value \< .05 was considered statistically significant. Statistical Package for the Social Sciences (SPSS 20.0 for Windows, SPSS, Chicago, IL, USA) was used for all statistical analyses. Graphs were created using GraphPad Prism (ver. 6.01; GraphPad Software, San Diego, CA, USA).

3. Results
==========

3.1. Down-regulation of HINT2 mRNA in HCC
-----------------------------------------

We performed quantitative real-time PCR in 106 paired samples of human HCC and corresponding non-tumor hepatic tissues to determine differences in *HINT2* mRNA expression. *HINT2* mRNA was down-regulated in approximately 70.8% of the paired tissue samples (Fig. [1](#F1){ref-type="fig"}A). The paired *t* test further demonstrated that *HINT2* was significantly (*P* \< .0001) down-regulated in tumor tissues compared with the non-tumor counterparts (Fig. [1](#F1){ref-type="fig"}B).

![Expression of HINT2 mRNA in hepatocellular carcinoma (HCC) tumor and corresponding non-tumor tissues. (A) HINT2 was down-regulated in most HCC tumor (70.8%) tissues compared with the paired non-tumor tissues. (B) The paired T-test revealed that HINT2 was significantly down-regulated (P \< 0.0001) in tumor compared with non-tumor counterpart tissues.](medi-98-e17815-g001){#F1}

3.2. Correlations between clinicopathological parameters and HINT2 expression
-----------------------------------------------------------------------------

The HCC patients were divided into 2 groups according to the median *HINT2* expression value, high and low *HINT2* expression, with 53 patients in each group. The clinicopathological variables of each group are listed in Table [1](#T1){ref-type="table"}, while all patients' demographic and clinicopathological characteristics are given in Supplementary Table 1. There was no significant correlation between any clinicopathological parameter and *HINT2* mRNA expression.

###### 

Correlation between *HINT2* expression in tumor tissue with clinicopathological factors in hepatocellular carcinoma patients.

![](medi-98-e17815-g002)

3.3. Prognostic significance of HINT2 expression
------------------------------------------------

We evaluated the prognostic significance of *HINT2* mRNA expression by Kaplan--Meier survival curves, which revealed no significant relationship between overall survival and *HINT2* expression (*P* \> .05) (Fig. [2](#F2){ref-type="fig"}A). However, further analysis demonstrated that patients with high *HINT2* expression in their tumor tissues have substantially longer recurrence-free survival compared with patients with low *HINT2* expression (*P* \< .05) (Fig. [2](#F2){ref-type="fig"}B). The TCGA data analysis verified a better survival with no HCC recurrence in high *HINT2* mRNA expression group (Fig. [2](#F2){ref-type="fig"}D), while overall survival was not affected by *HINT2* mRNA expression (Fig. [2](#F2){ref-type="fig"}C). Univariate analysis found that tumor size (\<5 vs ≥5 cm), tumor size (\<8 vs ≥8 cm) and *HINT2* expression were prognostic of recurrence-free survival (Table [2](#T2){ref-type="table"}). Multivariate analysis using the Cox proportional hazards model showed that tumor size (\<5 vs ≥5 cm; hazard ratio \[HR\] = 2.224, *P* = .025) and *HINT2* expression (HR = 0.560, *P* = .047) were independent prognostic factors in HCC patients (Table [2](#T2){ref-type="table"}).

![Survival curves of HCC patients with high and low *HINT2* expression were plotted using Kaplan--Meier analysis, and the differences in survival curves were evaluated by the log-rank test. (A) No significant difference in overall survival was found, but (B) recurrence-free survival rates differed significantly between the high and low *HINT2* expression groups. The TCGA data analysis revealed (C) overall survival was also not affected by *HINT2* expression, while (D) high *HINT2* expression group had better recurrence-free survival than low *HINT2* expression group.](medi-98-e17815-g003){#F2}
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Risk factor analysis of recurrence-free survival in tumor tissue.
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4. Discussion
=============

HINT proteins are the most conserved members of the HINT family.^\[[@R13]\]^*HINT2* was initially identified as a functional gene involved in mitochondrial import signaling in yeast.^\[[@R14]\]^ Korsisaari and colleagues found that *HINT2* was not required for murine development.^\[[@R15]\]^ There may be other HINT family members that functionally compensate for the loss of *HINT2*.^\[[@R16],[@R17]\]^ Lenglet et al validated that *HINT2* serves as a regulator of steroid formation by a calcium ion-independent pathway in human adenocarcinoma cells.^\[[@R8]\]^ A recent study showed that *HINT2* triggers mitochondrial calcium ion influx by regulating a mitochondrial calcium ion uniporter.^\[[@R18]\]^*HINT2* also plays a role in hepatic steatosis and hepatocellular energy metabolism.^\[[@R19],[@R20]\]^ Our research confirmed that *HINT2* mRNA was significantly down-regulated in HCC tumor tissues compared with corresponding non-tumor tissues among 106 paired samples, consistent with a previous study on HCC.^\[[@R7]\]^ However, we did not find any significant correlation between *HINT2* expression and clinical parameters in HCC patients, although our findings revealed that *HINT2* plays an important role in diverse biological processes of cellular metabolism. Considering our limited number of samples, we cannot exclude sampling error; therefore, additional samples are needed to verify this conclusion. Our survival analysis showed that HCC patients with high *HINT2* expression have a long recurrence-free survival period, suggesting that *HINT2* expression is a potential prognostic biomarker of HCC recurrence. Because most cases of tumor recurrence are attributed to the dissemination of metastatic HCC cells,^\[[@R21],[@R22]\]^ we speculate that low expression of *HINT2* may promote invasion and metastasis of HCC. We find no relation between *HINT2* expression with overall survive, it may due to that there is no uniform method for postoperative treatment of liver cancer, thus, the postoperative treatments for patients and time to follow-up are different, which can deeply affect the overall survive of patients. As shown in the multivariate analysis, tumor size (\<5 vs ≥5 cm) and *HINT2* expression are independent prognostic factors in HCC patients.

To date, several genes including castor zinc finger 1 (*CASZ 1*), cell division cycle associate 5(*CDCA5*) and *P16* serve as prognostic biomarkers for HCC.^\[[@R23]--[@R25]\]^ Like many other cancers, HCC development is a multistep process involving altered expression of several genes. *HINT2* is likely one of these genes, but may not be as efficient as the tumor suppressors P53 and Rb.^\[[@R26]\]^ However, our findings along with those of other current studies are not sufficient to recommend *HINT2* expression as a valuable predictor of HCC recurrence. Many problems should be taken into consideration for a new biomarker. The mow level of *HINT2* expression in HCC tissues does not make it a reliable biomarker. Unfortunately, recent studies have shown that there is no circulating cell-free *HINT2* DNA in blood samples.^\[[@R27],[@R28]\]^ In addition, based on our limited number of samples, it was difficult to extract a normal baseline value and to exclude other effects to minimize false-positive results.^\[[@R29]\]^ Therefore, further studies are necessary to verify the sensitivity and specificity of *HINT2* expression as a prognostic factor before its clinical application. Evaluating the protein expression of *HINT2* by immunohistochemical staining in HCC samples is indispensable, because various factors may impact the process of mRNA translation. Future investigations should focus on methods to up-regulate *HINT2* expression in HCC, for example, certain types of drugs or proteins. Stabilization and even up-regulation of *HINT2* expression may result in elevated sensitivity to mitochondrial apoptosis in HCC,^\[[@R7]\]^ hence improving the efficacy of chemotherapy and molecular targeted therapies.

In conclusion, we showed that *HINT2* expression is down-regulated in most HCC tissues. As a potential prognostic marker, low expression of *HINT2* in the tumor tissues of HCC patients may imply early recurrence after hepatectomy.
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